Vireo Growth (VREOF) Cash from Investing Activities Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | -308.05% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -41.51% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -139.86% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 129.18% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 1.71% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -366.90% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -96.43% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | -305.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 827.27% |
| Dec 31, 2025 | -261.33% |
| Sep 30, 2025 | -1,047.34% |
| Jun 30, 2025 | 1,167.20% |
| Mar 31, 2025 | -4.83% |
| Dec 31, 2024 | -1,423.26% |
| Sep 30, 2024 | -13.93% |
| Jun 30, 2024 | -119.24% |
| Mar 31, 2024 | -45.70% |
| Dec 31, 2023 | 79.11% |
| Sep 30, 2023 | -4.03% |
| Jun 30, 2023 | 2.90% |
| Mar 31, 2023 | 67.46% |
| Dec 31, 2022 | -110.51% |
| Sep 30, 2022 | 69.34% |
| Jun 30, 2022 | 75.46% |
| Mar 31, 2022 | 58.75% |
| Dec 31, 2021 | 2,033.38% |
| Sep 30, 2021 | -124.03% |
| Jun 30, 2021 | -575.16% |